New Model Launch: Introduction of the Rat CCl₄-Induced Acute Liver Injury Model
SMC Laboratories is pleased to announce the launch of a new in vivo platform: the rat CCl₄ (carbon tetrachloride)-induced acute liver injury model. This model reproduces acute hepatocellular injury and is well-suited for the non-clinical evaluation of compounds with hepatoprotective or anti-inflammatory properties.
Following a single intraperitoneal administration of CCl₄, serum ALT and AST levels rise significantly within 24 to 48 hours, establishing a clear and consistent evaluation window. These transaminase levels subsequently begin to decline, making the model particularly valuable for assessing both injury severity and recovery within a defined timeframe.
In addition to serum biomarkers, the model enables evaluation of inflammatory cytokine expression and liver regeneration markers, offering a multifaceted view of compound efficacy and mechanism of action.
This model is ideal for researchers seeking to:
-
Conduct rapid screening of hepatoprotective or anti-inflammatory agents
-
Evaluate compound efficacy using well-defined, reproducible endpoints
-
Investigate the mechanisms underlying liver injury and regeneration
SMC Laboratories offers flexible study designs, including customizable dosing regimens, administration routes, and assessment timelines. Optional endpoints such as histopathological evaluation and biomarker analysis can be integrated into a comprehensive efficacy assessment package.
For study protocols, sample data, or customized proposal requests, please feel free to contact us.
SMC remains committed to advancing preclinical research by expanding its disease model portfolio to support innovative drug discovery programs worldwide.